China NMPA Product Recall - Mycobacterium tuberculosis rpoB gene and mutation detection kit (real-time fluorescence PCR method) MTB/RIF Assay

The National Medical Products Administration (NMPA) published a Level III voluntary recall notice on November 14, 2022, concerning a diagnostic product manufactured by Cepheid AB and reported by Cepheid (Shanghai) Trading Co., Ltd. The affected product is the Mycobacterium tuberculosis rpoB gene and mutation detection kit (real-time fluorescence PCR method) MTB/RIF Assay, identified by Registration Certificate No. 20173406215. The core issue prompting this recall was an error in the expiration date labeling found on a specific model and batch of the kits. Accurate expiration dating is critical for medical devices to ensure their efficacy and safety throughout their intended shelf life, preventing the use of potentially compromised products. Under the regulatory framework of the NMPA, Cepheid initiated this voluntary recall. A Level III recall signifies that while the product violation is not likely to cause adverse health consequences, corrective action is necessary to address the non-compliance. The company is committed to rectifying this labeling discrepancy to uphold product quality standards. Further specifics regarding the exact models, specifications, and affected batches are detailed in the official "Medical Device Recall Event Report Form" accompanying the NMPA's announcement. This action underscores the importance of stringent quality control in medical device manufacturing and regulatory oversight to safeguard public health.